Wijnenga Maarten M J, Mattni Tariq, French Pim J, Rutten Geert-Jan, Leenstra Sieger, Kloet Fred, Taphoorn Martin J B, van den Bent Martin J, Dirven Clemens M F, van Veelen Marie-Lise, Vincent Arnaud J P E
Department of Neuro-Oncology, Erasmus MC Cancer Institute, Wytemaweg 80, 3015CN, Rotterdam, The Netherlands.
Department of Neurosurgery, Erasmus MC Cancer Institute, Wytemaweg 80, 3015CN, Rotterdam, The Netherlands.
J Neurooncol. 2017 May;133(1):137-146. doi: 10.1007/s11060-017-2418-8. Epub 2017 Apr 11.
Early resection is standard of care for presumed low-grade gliomas. This is based on studies including only tumors that were post-surgically confirmed as low-grade glioma. Unfortunately this does not represent the clinicians' situation wherein he/she has to deal with a lesion on MRI that is suspect for low-grade glioma (i.e. without prior knowledge on the histological diagnosis). We therefore aimed to determine the optimal initial strategy for patients with a lesion suspect for low-grade glioma, but not histologically proven yet. We retrospectively identified 150 patients with a resectable presumed low-grade-glioma and who were otherwise in good clinical condition. In this cohort we compared overall survival between three types of initital treatment strategy: a wait-and-scan approach (n = 38), early resection (n = 83), or biopsy for histopathological verification (n = 29). In multivariate analysis, no difference was observed in overall survival for early resection compared to wait-and-scan: hazard ratio of 0.92 (95% CI 0.43-2.01; p = 0.85). However, biopsy strategy showed a shorter overall survival compared to wait-and-scan: hazard ratio of 2.69 (95% CI 1.19-6.06; p = 0.02). In this cohort we failed to confirm superiority of early resection over a wait-and-scan approach in terms of overall survival, though longer follow-up is required for final conclusion. Biopsy was associated with shorter overall survival.
早期切除是疑似低级别胶质瘤的标准治疗方法。这是基于仅纳入术后经病理证实为低级别胶质瘤的肿瘤的研究。不幸的是,这并不能代表临床医生的实际情况,即临床医生必须处理MRI上疑似低级别胶质瘤的病变(即术前没有组织学诊断信息)。因此,我们旨在确定针对疑似低级别胶质瘤但尚未经组织学证实的患者的最佳初始治疗策略。我们回顾性地纳入了150例可切除的疑似低级别胶质瘤患者,且这些患者临床状况良好。在这个队列中,我们比较了三种初始治疗策略的总生存期:等待观察并定期扫描(n = 38)、早期切除(n = 83)或进行活检以进行组织病理学验证(n = 29)。多因素分析显示,与等待观察并定期扫描相比,早期切除的总生存期无差异:风险比为0.92(95%可信区间0.43 - 2.01;p = 0.85)。然而,与等待观察并定期扫描相比,活检策略的总生存期较短:风险比为2.69(95%可信区间1.19 - 6.06;p = 0.02)。在这个队列中,我们未能证实早期切除在总生存期方面优于等待观察并定期扫描的方法,不过最终结论还需要更长时间的随访。活检与较短的总生存期相关。